Áreas terapeúticas

Type 1 diabetes is underpinned by autoimmune activity against insulin-producing beta cells, as explained in this video.

Monitoring people with early-stage autoimmune T1D may reduce the risk of serious complications, such as DKA.

T1D is an autoimmune disease whereby autoreactive T-cells drive progressive beta-cell damage and destruction, ultimately leading to insulin deficiency, dysglycemia, and hyperglycemia. 

An overview of the screening methods for autoimmune type 1 diabetes (T1D).

A brief overview of the tools available for monitoring people with presymptomatic autoimmune type 1 diabetes, and the pros and cons for each method.

Expert consensus on monitoring individuals with T1D islet autoantibodies: detection, monitoring frequency, and psychosocial support for managing autoimmune T1D.

Staging of autoimmune T1D allows us to track the progressive nature of the disease, from autoimmunity through to insulin dependence. 

Screening for autoimmune T1D involves testing for autoantibodies that are markers of destruction of insulin-producing beta cells.

Why and Who: an overview of the key considerations and decisions that inform screening people for islet autoantibodies.

An overview of the stages of autoimmune type 1 diabetes, from the development of autoimmunity through to insulin dependence. 

The burden associated with a diagnosis of autoimmune T1D can be wide-ranging. This video describes the impact of diagnosis on an individual and their family.